Phase II study of XELIRI with bevacizumab as second-line therapy for metastatic colorectal cancer - Beyond Progression Disease of capecitabine and bebacizumab

Trial Profile

Phase II study of XELIRI with bevacizumab as second-line therapy for metastatic colorectal cancer - Beyond Progression Disease of capecitabine and bebacizumab

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Irinotecan (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Aug 2015 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan record.
    • 13 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top